Solid Tumors, No Specified Mutations

- 9782: A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors
- 10145: Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas
- 10014: A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
- 10130: A Phase I Study of Single Agent Tazemetostat in Subjects with Advanced Solid Tumors or B-Cell Lymphomas with Hepatic Dysfunction
- 5914: A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
- 9938: Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors
- 9914: A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
- 10130: A Phase I Study of Single Agent Tazemetostat in Subjects with Advanced Solid Tumors or B-Cell Lymphomas with Hepatic Dysfunction
- 9999: A Phase 1 Trial of the Combination of the Heat Shock Protein -90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors
- 10001: A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
- 9591: A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
- 10292: Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors
- 9837: Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin (Arm A: advanced solid tumors; Arm B: malignant pleural or peritoneal mesothelioma)
- * 10299: A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
- * 10315: A Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: June 19, 2019